Osiris Therapeutics Inc. (OSIR) has been rising for the majority of early trade Friday morning and is now up 1.02 at $9.09 on above average volume.
Osiris Therapeutics has climbed sharply in the last 3 sessions and is now trading at a new high for the year. The company announced Thursday that it received consent from New Zealand to market its stem cell therapy Prochymal, for the treatment of acute graft-vs.-host disease in children.
For comments and feedback: editorial@rttnews.com